Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01271998 · ClinicalTrials.gov registry record · Phase 1
Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg
A Phase 1 study, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01271998 is a Phase 1 study that has completed, run by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 20 participants.
The verdict
NCT01271998, a Phase 1 study, has completed, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the steady-state plasma pharmacokinetics (PK) and properties of TR-700 into the pulmonary epithelial lining fluid (ELF) and alveolar macrophages (AM) of healthy volunteers.
Interventions
- DRUG TR-701 FA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-12-08 |
| Est. Completion | 2011-01-03 |
| Phase | Phase 1 |
Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)18 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01271998
The ClinicalTrials.gov registry entry for NCT01271998 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TR-701 FA is the first listed.
NCT01271998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01271998 about?
NCT01271998 is a clinical study titled "Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg". The primary purpose of this study is to determine the steady-state plasma pharmacokinetics (PK) and properties of TR-700 into the pulmonary epithelial lining fluid (ELF) and alveolar macrophages (AM) of healthy volunteers.
What is the current status of trial NCT01271998?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-12-08. Estimated completion is 2011-01-03.
What interventions are being tested in trial NCT01271998?
The interventions under investigation include: TR-701 FA (DRUG).
Who is sponsoring clinical trial NCT01271998?
This trial is sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.